Krystal Biotech (KRYS) Stock Price, News & Analysis

Company Overview

Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition. KB103 has advanced through clinical trials under orphan drug and breakthrough therapy designations granted by the U.S. Food and Drug Administration. In addition to DEB, Krystal Biotech is advancing a second program, KB105, aimed at correcting the genetic defect underlying pseudoxanthoma elasticum. The company maintains an in-house cGMP manufacturing facility to support both development activities and future commercialization efforts.

Since its initial public offering on the Nasdaq in July 2019, Krystal Biotech has expanded its clinical and regulatory footprint, enrolling patients in multiple U.S. and international study sites. The company is led by a management team with deep expertise in gene therapy development and regulatory strategy. With a growing pipeline and a dedicated manufacturing infrastructure, Krystal Biotech is positioned to advance its targeted gene therapies through late-stage development and toward potential approval.

Key Stats

• Today's Range: $298.92 to $312.38
• 50-Day Range: $245.39 to $316.30
• 52-Week Range: $127.99 to $319.48
• Volume: 264,899 shs
• Average Volume: 270,120 shs
• Market Capitalization: $9.07 billion
• P/E Ratio: 41.15
• Dividend Yield: N/A
• Price Target: $324.11
• Consensus Rating: Moderate Buy

Krystal Biotech Stock Analysis - MarketRank™

Krystal Biotech scored higher than 61% of companies evaluated by MarketBeat, and ranked 494th out of 865 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.8 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Krystal Biotech has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on no strong buy ratings, 10 buy ratings, 2 hold ratings, and no sell ratings.

Upside/Downside

The consensus price target for Krystal Biotech is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Krystal Biotech has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 34.36%

Earnings Growth

Earnings for Krystal Biotech are expected to grow by 34.36% in the coming year, from $7.83 to $10.52 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Krystal Biotech is 41.15, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.67.

Price to Earnings Ratio vs. Sector

The P/E ratio of Krystal Biotech is 41.15, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 24.03.

Price to Book Value per Share Ratio

Krystal Biotech has a P/B Ratio of 7.32. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.43% of the float of Krystal Biotech has been sold short.

Short Interest Ratio / Days to Cover

Krystal Biotech has a short interest ratio ("days to cover") of 8.01.

Change versus previous month

Short interest in Krystal Biotech has recently increased by 2.83%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Krystal Biotech does not currently pay a dividend.

Dividend Growth

Krystal Biotech does not have a long track record of dividend growth.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.82

News Sentiment

Krystal Biotech has a news sentiment score of 0.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Krystal Biotech this week, compared to 5 articles on an average week.

Search Interest

25 people have searched for KRYS on MarketBeat in the last 30 days. This is an increase of 2,400% compared to the previous 30 days.

MarketBeat Follows

7 people have added Krystal Biotech to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days.

Company Ownership

• Score: 1.9 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Krystal Biotech insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $193,903.00 in company stock.

Percentage Held by Insiders

13.10% of the stock of Krystal Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

86.29% of the stock of Krystal Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/04/2026
• Today: 6/04/2026
• Next Earnings (Estimated): 8/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:KRYS
• CIK: 1711279
• Web: www.krystalbio.com
• Phone: (412) 586-5830
• Fax: N/A
• Employees: 210
• Year Founded: 2017

Price Target and Rating

• Average Price Target for Krystal Biotech: $324.11
• High Price Target: $378.00
• Low Price Target: $284.00
• Potential Upside/Downside: +5.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.83
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): $7.48
• Trailing P/E Ratio: 41.15
• Forward P/E Ratio: 39.31
• P/E Growth: N/A
• Net Income: $204.83 million
• Net Margins: 53.92%
• Pretax Margin: 49.68%
• Return on Equity: 19.25%
• Return on Assets: 17.62%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.46
• Quick Ratio: 9.06

Sales & Book Value

• Annual Sales: $417.30 million
• Price / Sales: 21.74
• Cash Flow: $7.43 per share
• Price / Cash Flow: 41.40
• Book Value: $42.06 per share
• Price / Book: 7.32

Miscellaneous

• Outstanding Shares: 29,480,000
• Free Float: 25,618,000
• Market Cap: $9.07 billion
• Optionable: Optionable
• Beta: 0.53